Free Trial

uniQure (QURE) Competitors

uniQure logo
$15.78 +1.18 (+8.08%)
Closing price 04:00 PM Eastern
Extended Trading
$15.87 +0.09 (+0.57%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QURE vs. INDV, SRRK, APLS, MOR, AMRX, NAMS, HCM, RARE, XENE, and CRNX

Should you be buying uniQure stock or one of its competitors? The main competitors of uniQure include Indivior (INDV), Scholar Rock (SRRK), Apellis Pharmaceuticals (APLS), MorphoSys (MOR), Amneal Pharmaceuticals (AMRX), NewAmsterdam Pharma (NAMS), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), Xenon Pharmaceuticals (XENE), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry.

uniQure vs. Its Competitors

uniQure (NASDAQ:QURE) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

78.8% of uniQure shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 4.8% of uniQure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Indivior had 9 more articles in the media than uniQure. MarketBeat recorded 11 mentions for Indivior and 2 mentions for uniQure. uniQure's average media sentiment score of 1.94 beat Indivior's score of 1.04 indicating that uniQure is being referred to more favorably in the media.

Company Overall Sentiment
uniQure Very Positive
Indivior Positive

uniQure has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Indivior has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500.

Indivior has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
uniQure$27.12M31.93-$239.56M-$3.92-4.03
Indivior$1.19BN/A$2M$0.6237.37

Indivior has a net margin of 6.65% compared to uniQure's net margin of -1,387.98%. Indivior's return on equity of -86.28% beat uniQure's return on equity.

Company Net Margins Return on Equity Return on Assets
uniQure-1,387.98% -1,010.74% -33.27%
Indivior 6.65%-86.28%16.26%

uniQure currently has a consensus price target of $37.45, indicating a potential upside of 137.35%. Indivior has a consensus price target of $19.60, indicating a potential downside of 15.41%. Given uniQure's higher possible upside, equities research analysts clearly believe uniQure is more favorable than Indivior.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
uniQure
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
3.00
Indivior
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17

Summary

Indivior beats uniQure on 10 of the 16 factors compared between the two stocks.

Get uniQure News Delivered to You Automatically

Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QURE vs. The Competition

MetricuniQureMED IndustryMedical SectorNASDAQ Exchange
Market Cap$801.06M$3.10B$5.62B$9.84B
Dividend YieldN/A2.23%4.61%4.07%
P/E Ratio-4.0320.4930.2925.74
Price / Sales31.93356.37463.41115.83
Price / CashN/A43.0338.2159.48
Price / Book-225.438.608.826.15
Net Income-$239.56M-$54.65M$3.25B$265.06M
7 Day Performance17.32%5.43%4.05%2.80%
1 Month Performance8.45%6.75%4.32%1.68%
1 Year Performance135.52%31.59%36.25%29.59%

uniQure Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
QURE
uniQure
2.7998 of 5 stars
$15.78
+8.1%
$37.45
+137.4%
+107.4%$801.06M$27.12M-4.03500Positive News
Analyst Upgrade
Gap Up
INDV
Indivior
3.1976 of 5 stars
$22.29
+1.3%
$19.60
-12.1%
+87.5%$3.07B$1.17B35.951,051
SRRK
Scholar Rock
4.481 of 5 stars
$31.46
-1.5%
$45.14
+43.5%
+229.4%$3.02B$33.19M-10.81140Analyst Revision
APLS
Apellis Pharmaceuticals
4.0099 of 5 stars
$23.85
-2.1%
$34.12
+43.1%
-25.6%$3.01B$781.37M-13.10770Short Interest ↑
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
AMRX
Amneal Pharmaceuticals
3.054 of 5 stars
$8.84
+3.5%
$11.60
+31.2%
+19.6%$2.77B$2.79B884.888,100News Coverage
Insider Trade
NAMS
NewAmsterdam Pharma
3.5296 of 5 stars
$24.37
-3.7%
$41.20
+69.1%
+49.6%$2.74B$64.01M-15.044Analyst Revision
HCM
HUTCHMED
2.6309 of 5 stars
$15.48
+3.2%
$28.00
+80.9%
-21.2%$2.70B$630.20M0.001,811Positive News
RARE
Ultragenyx Pharmaceutical
4.6657 of 5 stars
$27.39
-0.5%
$81.50
+197.6%
-44.1%$2.64B$560.23M-4.951,294Analyst Revision
XENE
Xenon Pharmaceuticals
2.0303 of 5 stars
$34.11
+2.0%
$54.33
+59.3%
-2.9%$2.62B$9.43M-10.56210Trending News
Earnings Report
Analyst Forecast
Analyst Revision
CRNX
Crinetics Pharmaceuticals
3.4338 of 5 stars
$27.38
+2.0%
$68.86
+151.5%
-40.2%$2.58B$1.04M-6.66210News Coverage
Earnings Report
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:QURE) was last updated on 8/14/2025 by MarketBeat.com Staff
From Our Partners